Search Results
Your search for The ASCO Post matches 17137 pages
Showing 5051 - 5100Trends in AYA Cancer Incidence in the United States Over 4 Decades
Cancer cases in adolescents and young adults (AYAs) have risen by 30% during the past 4 decades, with rates of kidney cancer increasing at the greatest rate, according to findings published by Scott et al in JAMA Network Open. The team said further research into screening, diagnosis, and treatment...
Postoperative Cancer Surgery Mortality Rates Have Improved, but Gap Still Exists Between Black and White Patients
Mortality rates after cancer surgery declined for Black as well as White patients during a recent 10-year period, although the mortality gap between the two groups did not narrow, according to new research published by Miranda Lam, MD, MBA, and colleagues in JAMA Network Open. The findings present...
ASH 2020: ctDNA May Indicate Increased Risk of Relapse After Stem Cell Transplant in Patients With DLBCL
Many patients with diffuse large B-cell lymphoma (DLBCL) may be cured by autologous stem cell transplant, but as many as half eventually relapse. New research presented by Reid Merryman, MD, and colleagues at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition suggests...
ESMO Immuno-Oncology 2020: Does Pleural Effusion Affect Survival in Patients Treated With Immunotherapy for NSCLC?
Patients with non–small cell lung cancer (NSCLC) who have pleural effusion, especially those requiring pleural evacuation, experienced poorer survival when treated with immune checkpoint inhibitors, according to findings presented by Epaillard et al at the European Society for Medical Oncology...
SABCS 2020: Patient-Reported Outcomes From the Phase III IMpassion031 Trial
Adding an immune checkpoint inhibitor to a standard chemotherapy regimen for patients with early-stage triple-negative breast cancer did not affect patients’ ability to perform day-to-day activities more than treatment with chemotherapy alone, according to research presented by Elizabeth...
FDA Issues Emergency Use Authorization for First COVID-19 Vaccine
On December 11, the U.S. Food and Drug Administration (FDA) issued the first emergency use authorization (EUA) for a vaccine for the prevention of COVID-19 caused by SARS-CoV-2 in individuals aged 16 and older. The EUA allows the Pfizer-BioNTech COVID-19 vaccine to be distributed in the United...
ASH 2020: Phase II ZUMA-12 Study Investigates Axicabtagene Ciloleucel for High-Risk Large B-Cell Lymphoma
The phase II ZUMA-12 trial found that axicabtagene ciloleucel, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, is a safe and effective therapy for patients with high-risk large B-cell lymphoma. These results were presented by Sattva S. Neelapu, MD, and colleagues at the 2020 ...
SABCS 2020: Can Mindfulness Meditation and Survivorship Education Help to Reduce Depression in Young Breast Cancer Survivors?
New research showed that behavioral interventions—mindfulness meditation and survivorship education classes—may be effective in reducing depressive symptoms in younger breast cancer survivors. This patient population often experiences the highest levels of depression, stress, and fatigue, which may ...
Andrew D. Zelenetz, MD, PhD, on Mantle Cell Lymphoma: Expert Perspective on Key Clinical Trials
Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, offers his expert views on five treatment studies in mantle cell lymphoma focusing on the next-generation BTK inhibitor LOXO-305; lisocabtagene maraleucel; minimal residual disease monitoring following autologous stem cell...
Andrew D. Zelenetz, MD, PhD, on Mantle Cell Lymphoma: Immunochemotherapy Plus Lenalidomide
Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses phase II results from a single-center study that explored a novel approach for high-risk patients with mantle cell lymphoma. Among patients with TP53 wild-type disease, the data suggested this treatment was effective...
Debra A. Pratt, MD, on Time to Completion of Breast Cancer Treatment and Survival
In her recent study, Debra A. Pratt, MD, of the Cleveland Clinic, showed that when breast cancer treatment using any of three modalities takes longer than 38 weeks, it is associated with a decrease in survival, regardless of the receptor status. Patients with breast cancer who received neoadjuvant...
Chirag Shah, MD, on Assessing DCIS Recurrence Risk
Chirag Shah, MD, of the Cleveland Clinic, discusses the impact of DCISionRT testing on radiation therapy recommendations for patients with ductal carcinoma in situ following lumpectomy. His study found that despite using traditional favorable-risk criteria, radiation recommendations were changed in ...
Meletios A. Dimopoulos, MD, on Multiple Myeloma: Daratumumab, Pomalidomide, and Dexamethasone
Meletios A. Dimopoulos, MD, of the University of Athens, discusses data from the phase III APOLLO study, which evaluated the use of subcutaneous daratumumab plus pomalidomide and dexamethasone, vs pomalidomide and dexamethasone alone, in patients with relapsed or refractory multiple myeloma...
Ari M. Melnick, MD, on Activated B-Cell–Like DLBCL: Gain-of-Function Mutations and Resistance to Ibrutinib
Ari M. Melnick, MD, of Weill Cornell Medicine, discusses the BCL10 mutation in patients with activated B-cell–like diffuse large B-cell lymphoma, and his study results which showed that the mutation should be considered as a biomarker for ibrutinib resistance so that alternative targeted treatments ...
SITC Announces Creation of Steven A. Rosenberg, MD, PhD, Endowed Scholars Fund
The Society for Immunotherapy of Cancer (SITC) has announced the creation of the Steven A. Rosenberg, MD, PhD, Endowed Scholars Fund. Established in honor of Dr. Rosenberg, this fund recognizes his many contributions to the field by supporting investigators who are emerging leaders in...
Sara Federico, MD, Receives NCI Award for Leadership in Developing Clinical Trials for Pediatric Cancer
Sara Federico, MD, associate member of the Department of Oncology at St. Jude Children’s Research Hospital, has received the 2020 Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute (NCI). This award recognizes and supports outstanding mid-career clinical...
2020 E. Donnall Thomas Lecture and Prize Awarded to Toshio Suda, MD, PhD
The American Society of Hematology (ASH) presented the 2020 E. Donnall Thomas Lecture and Prize to Toshio Suda, MD, PhD, of the National University of Singapore and Japan’s International Research Center for Medical Sciences, Kumamoto University, for his outstanding contributions to the field of...
2020 William Dameshek Prize Awarded to Adolfo Ferrando, MD, PhD
The American Society of Hematology (ASH) presented the 2020 William Dameshek Prize to Adolfo Ferrando, MD, PhD, of Columbia University Institute for Cancer Genetics in New York, for his outstanding research on the impact of NOTCH1 mutations on T-cell acute lymphoblastic leukemia (ALL). “I am...
ASH Awards Henry M. Stratton Medal to Hematology Researchers
The American Society of Hematology (ASH) recognized Michelle Le Beau, PhD, of the University of Chicago and the University of Chicago Medicine Comprehensive Cancer Center, and Maria Domenica Cappellini, MD, of the University of Milan in Italy, with the 2020 Henry M. Stratton Medal for their...
New Rules on Health-Care Price Transparency and Coverage for COVID-19 Vaccines
ON OCTOBER 28, the U.S. Department of Health and Human Services (HHS), the U.S. Department of Labor, and the U.S. Department of the Treasury released the coverage transparency final rule. Building on earlier administration actions requiring hospitals to disclose standard charges and negotiated...
Shilpi Gupta, MD, Joins Atlantic Health System Cancer Care’s Comprehensive Breast Health Program
Atlantic Health System Cancer Care recently announced that fellowship-trained medical oncologist Shilpi Gupta, MD, has joined Morristown Medical Center’s comprehensive breast health program, where her focus is breast oncology and research. Dr. Gupta is on staff at Atlantic Hematology Oncology at...
Albert Einstein College of Medicine Researchers Receive $5 Million Grant From the National Institutes of Health
A TEAM OF SCIENTISTS from Albert Einstein College of Medicine has received a 5-year, $4.9 million grant from the National Institutes of Health (NIH) to establish a research center to investigate human immunodeficiency virus (HIV)- and human papillomavirus (HPV)-related cancers in Africa. The...
City of Hope Orange County Names Edward S. Kim, MD, MBA, Its Physician-in-Chief
CITY OF HOPE ORANGE COUNTY recently announced the appointment of cancer researcher and clinician Edward S. Kim, MD, MBA, as Senior Vice President and Vice Physician-in-Chief at City of Hope and Orange County Physician-in-Chief. “Dr. Kim has a depth and breadth of cancer expertise that is well...
Abraham Chachoua, MD, Announced as New Director of Perlmutter Cancer Center’s Lung Cancer Center
New York University (NYU) Langone Health’s Perlmutter Cancer Center recently appointed Abraham Chachoua, MD, as the new Director of Perlmutter Cancer Center’s Lung Cancer Center. Dr. Chachoua currently serves as the Jay and Isabel Fine Professor of Oncology and Professor of Urology at NYU...
World Health Organization Launches First-Ever Global Commitment to Eliminate Cervical Cancer
THE WORLD HEALTH ORGANIZATION (WHO) has launched the Global Strategy to Accelerate the Elimination of Cervical Cancer, outlining three key steps: vaccination, screening, and treatment. Successful implementation of all three could reduce more than 40% of new cases of the disease and 5 million...
Huntsman Cancer Institute Leadership Announces Two New Appointments
Huntsman Cancer Institute (HCI) at the University of Utah recently announced new leadership appointments for two long-standing cancer center members. Chief Academic Officer Brad Cairns, PhD, has accepted an appointment as Chief Academic Officer at HCI. In this new role, Dr. Cairns will lead...
The Problem of Heterogeneity Within Stage
The more senior of this duo grew up with prognostication by disease stage and was taught that all stage IV cancers behaved the same. In the past 3 decades, we have become much more cognizant of the heterogeneity in outcome within stage. Individual Kaplan-Meier plots by stage separate well but hide...
Staying a Step Ahead of Cancer
When I was diagnosed with metastatic breast cancer in 2018, my first thought was, I hope my three young children do not lose two parents to cancer. My husband, Ricky, had survived two bouts of cancer, early-stage colorectal cancer and, most recently, stage I kidney cancer. Like Ricky’s two...
Project Orbis: Partnering With International Regulatory Agencies to Bring Earlier Global Access to Novel Cancer Treatments
OCE Insights is an occasional department developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, Preeti Narayan, MD, a medical oncologist and clinical reviewer on the Breast and Gynecologic Disease Team,...
Continued Progression-Free and Overall Survival Superiority of First-Line Pembrolizumab/Axitinib vs Sunitinib
As reported in The Lancet Oncology by Thomas Powles, MD, of Barts Cancer Institute, London, and colleagues, extended follow-up of the phase III KEYNOTE-426 trial shows continued progression-free and overall survival superiority with pembrolizumab/axitinib vs sunitinib alone in first-line treatment ...
Bristol Myers Squibb Foundation and National Medical Fellowships Launch Program to Increase Diversity in Clinical Trials
The Bristol Myers Squibb Foundation and National Medical Fellowships recently announced their new partnership, which is aimed at improving diversity in clinical trials. Leveraging $100 million of the previously announced commitment to diversity and inclusion from Bristol Myers Squibb and the...
What Is the Measure of Minimal Residual Disease in AML?
Relapse is the primary obstacle to cure in leukemia. The term minimal residual disease (MRD) was coined in the early 1990s to describe finding a disease-specific marker in the context of a morphologic-appearing remission. The technique first used for MRD detection was the Southern blot (!), but the ...
Older Woman With Eye Tumor
The text and photograph here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The Antiseptic Era 1876–1900 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photograph appears courtesy of Stanley B. Burns, MD, and The Burns...
Facing Life’s Adversities, Even Cancer, From the Back of a Horse Named Buddy
“A bald eagle skims along the bluff where windblown Douglas firs, their exposed roots like talons, grip the eroding cliffs. Gulls circle and warn the bird of prey not to get too close. One hundred fifty feet below, the Salish Sea crashes and stretches west to the Pacific.” So begins Wild Ride Home: ...
Edward J. Benz, Jr, MD, Receives 2020 ASH Award for Leadership in Promoting Diversity
The 2020 American Society of Hematology (ASH) Award for Leadership in Promoting Diversity was awarded to Edward J. Benz, Jr, MD, President and Chief Executive Officer Emeritus of the Dana-Farber Cancer Institute and the Richard and Susan Smith Distinguished Professor at Harvard Medical School. Dr....
Addressing Disparities in Care Among Black Men and Women With Cancer
The American Cancer Society and Pfizer have approved grants totaling more than $3.7 million focused on reducing racial disparities in care and helping to optimize cancer outcomes for Black men and women in 10 communities. The goal is to address systemic race-related barriers and disparities in the...
The Lung Microbiome May Affect Lung Cancer Pathogenesis and Prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced-stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.1 “The...
Dana-Farber/Brigham and Women’s Cancer Center and Stamford Hospital Expand Collaboration
Stamford Health and Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) formally announced an exclusive, expanded collaboration to increase access to DF/BWCC experts and resources for patients at Stamford Health’s Carl & Dorothy Bennett Cancer Center. Stamford Health first joined the...
Understanding Breast Cancer Diagnosis and Treatment Disparities in Resource-Challenged Nations
Cancer is the second leading cause of death in the Caribbean. Adding to this growing burden, many of the nations in this geographically spread region have under-resourced health-care systems and a lack of cohesive approaches to the delivery of cancer care. To shed light on the public health...
Researchers Join $10 Million Project to Better Understand Sex Differences in Brain Cancer Outcomes
Researchers from Penn State College of Medicine are participating in a $10 million project to better understand why men and women with a common and deadly type of brain cancer have different survival rates. The investigators hope the study results can be used to develop new therapeutic approaches...
ASH Recognizes Admiral Brett Giroir, MD, With 2020 Outstanding Service Award
The American Society of Hematology (ASH) honored Admiral Brett Giroir, MD, Assistant Secretary for Health at the U.S. Department of Health and Human Services (HHS), for his outstanding support of hematology research and patient care. At the all-virtual annual meeting, Admiral Giroir received the...
Hannah Hazard-Jenkins, MD, Named Permanent Director of the WVU Cancer Institute
Hannah Hazard-Jenkins, MD, Associate Chair of Surgery for Cancer Services, has been named permanent Director of the West Virginia University (WVU) Cancer Institute after having served in the position on an interim basis since January. “As a native West Virginian, it is my honor to serve in this...
Daniel D. Von Hoff, MD, FACP, FASCO, FAACR, Receives Inaugural AACR Scientific Achievement Award Established in His Honor
The American Association for Cancer Research (AACR) recently announced that Daniel D. Von Hoff, MD, FACP, FASCO, FAACR, will receive the inaugural AACR Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research. Dr. Von Hoff is being recognized for his...
FDA and AACR Launch Project Livin’ Label
The American Association for Cancer Research (AACR) and the U.S. Food and Drug Administration (FDA) will collaborate on Project Livin’ Label, a new educational initiative that aims to foster broad understanding of specific oncology product labels and increase awareness of recent oncology drug FDA...
Erratum
In the November 10, 2020, issue of The ASCO Post, the article “Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Chile” contained errors with regard to the head shots of the coauthors. A photo of Augusto León G-H, MD (the son of another coauthor with a similar name), was...
Discerning the Underlying Mechanisms of Endometrial Cancer Disparities in Black Women
Endometrial cancer is the fourth most common cancer diagnosed in the United States, and the seventh most common cause of cancer death among women.1 This year, nearly 66,000 women will be diagnosed with the cancer, and about 12,600 will die of the disease.2 And although endometrial cancer is one of...
SABCS 2020: Patients With Breast Cancer Undergoing Radiotherapy May Have Underrecognized Side Effects
Among patients with breast cancer treated with radiotherapy, symptoms were commonly underrecognized in reports of pain, pruritus, edema, and fatigue, with younger patients and Black patients having significantly increased odds of symptom underrecognition. These findings were reported by Reshma...
CU Cancer Center Leukemia Researcher Receives NCI Outstanding Investigator Award
Craig Jordan, PhD, University of Colorado (CU) Cancer Center member and Chief of the Hematology Division in the CU School of Medicine, was awarded a 2020 National Cancer Institute (NCI) Outstanding Investigator Award. This 7-year grant supports investigators with outstanding records of...
SABCS 2020: Opioid and Sedative-Hypnotic Use After Mastectomy With Reconstructive Surgery
Women who undergo mastectomy with reconstructive surgery as part of breast cancer treatment may face the risk of persistent use of opioids and sedative-hypnotic drugs, according to data presented by Jacob Cogan, MD, and colleagues at the 2020 San Antonio Breast Cancer Symposium (Abstract GS3-08)....
SABCS 2020: Meta-analysis of Pregnancy Outcomes in Breast Cancer Survivors
A large meta-analysis of breast cancer survivors of childbearing age indicated that they are less likely than the general public to become pregnant and may face a higher risk of certain complications, such as preterm labor. However, most survivors who do become pregnant deliver healthy babies and...
